)

Vor Biopharma (VOR) investor relations material
Vor Biopharma Stifel Virtual Immunology and Inflammation Forum summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Strategic repositioning and asset acquisition
Company restructured as 'Vor 2.0' around telitacicept, a late-stage immunology asset licensed from RemeGen with global rights ex-China.
Telitacicept is a dual BAFF/APRIL inhibitor, targeting both upstream and downstream B-cell pathways for durable efficacy and disease modification.
Over 70,000 patients treated in China, with 3,000 in clinical trials and proven efficacy in three indications; two more PLAs being filed.
Focused on large, underserved indications such as myasthenia gravis and Sjögren’s disease.
Assembled a world-class leadership team to execute on these opportunities.
Differentiation and clinical data
Telitacicept closely mimics the wild type TACI receptor, providing optimal inhibition of BAFF and APRIL and balanced, safe therapy.
Demonstrates consistent efficacy across immunoglobulin types (IgG, IgA, IgM) and normalizes B cells, addressing disease root causes.
Offers potential advantages over FCRN antagonists and complement inhibitors by targeting broader disease mechanisms.
Myasthenia gravis program
Myasthenia gravis is a key focus, with 90,000 U.S. patients and high unmet need for durable, disease-modifying treatments.
Phase III China trial showed unprecedented, durable activity on MGADL endpoint, with benefits enduring through 24 and 48 weeks.
Long-term data to be presented at AANEM, highlighting continued improvement and disease trajectory modification.
Global phase III trial is enrolling, leveraging seamless transition from RemeGen and high-quality China data.
Study design accounts for potential higher placebo response in global settings, aiming to replicate best-in-disease results.
Next Vor Biopharma earnings date

Next Vor Biopharma earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage